Pre-Made Ontorpacept Biosimilar, Fusion Protein targeting CD47 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IAP/MER6/OA3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ontorpacept is a fusion protein consisting of Signal regulatory protein ¦Á (SIRP¦Á) fused to the human IgG1 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells